Which digital health platforms raised money?

This blog post has been written by the person who has mapped the digital health funding market in a clean and beautiful presentation

Digital health funding reached $25.1 billion in 2024 and $12.1 billion in the first half of 2025, marking a strong recovery driven by AI innovations and mega-deals.

This resurgence reflects investor confidence in proven technologies, with average deal sizes jumping from $15.5 million in 2024 to $32.1 million in H1 2025. Strategic partnerships between startups and major corporations are reshaping how healthcare innovation gets funded and scaled.

And if you need to understand this market in 30 minutes with the latest information, you can download our quick market pitch.

Which digital health companies raised the most significant funding rounds in 2024 and H1 2025?

Xaira Therapeutics dominated with a $1 billion strategic round led by ARCH Venture Partners and Foresite Labs, focusing on cell therapy platforms using AI-driven drug discovery.

Formation Bio secured $375 million in Series D funding from Andreessen Horowitz, leveraging computational biology to accelerate clinical trials and drug development timelines. Freenome raised $254 million in Series E funding backed by Roche, specifically targeting AI-powered early cancer detection through blood-based screening technologies.

PharmEasy completed a $216 million Series G1 round led by MEMG, expanding their direct-to-consumer pharmacy operations across emerging markets. Abridge raised $150 million in Series C from Lightspeed and Redpoint, developing large language models for automated clinical documentation that reduce physician administrative burden by 60-70%.

Talkiatry secured $130 million in Series C funding from Andreessen Horowitz, building virtual mental health infrastructure that connects patients with psychiatrists within 48 hours. Transcarent closed a $126 million Series D round led by General Catalyst and 7wire Ventures, creating employee benefits navigation platforms that reduce healthcare costs by 15-20% for enterprise clients.

Need a clear, elegant overview of a market? Browse our structured slide decks for a quick, visual deep dive.

How much total capital flowed into digital health in 2024 versus the first half of 2025?

Digital health attracted $25.1 billion across 1,623 deals in 2024, representing a significant recovery from previous years' funding drought.

The first half of 2025 already generated $12.1 billion in funding through 615 deals, suggesting a potential $24-26 billion full-year total if current momentum continues. This represents a 107% increase in average deal size from $15.5 million in 2024 to $32.1 million in H1 2025.

Mega-deals ($100+ million) comprised 38% of total funding in 2024 but jumped to 51% in Q1 2025 alone, indicating investor preference for late-stage, proven companies over early-stage ventures. The concentration effect shows the top 10 deals in H1 2025 captured approximately 35% of total sector funding.

Geographic distribution shifted notably, with Europe experiencing a "breakout quarter" in Q1 2025, capturing 23% of global funding compared to 15% in 2024. Asia-Pacific maintained steady 18-20% market share, while US dominance decreased from 67% to 57% as international markets matured.

If you want fresh and clear data on this market, you can download our latest market pitch deck here

Who are the most active investors backing digital health startups and their portfolio companies?

Andreessen Horowitz (a16z) emerged as the most aggressive digital health investor, backing Formation Bio ($375M), Talkiatry ($130M), and Ambience Healthcare across multiple rounds totaling over $600 million in 2024-2025.

General Catalyst led or co-led deals worth $400+ million, including Transcarent ($126M), Commure, and several undisclosed mega-deals focusing on healthcare infrastructure and workflow optimization. Bessemer Venture Partners maintained significant positions in Hinge Health, Abridge ($150M), and Bright Health, concentrating on proven revenue models.

GV (Google Ventures) deployed capital across 160+ digital health investments since 2020, with notable recent focus on AI diagnostics and clinical decision support platforms. Oak HC/FT specialized in healthcare IT infrastructure, backing Athenahealth, Castlight Health, and PharMEDium with deals averaging $50-80 million.

European investors gained prominence, with Index Ventures, Heartcore Capital, and Octopus Ventures leading the region's funding surge. These firms focused on regulatory-compliant AI solutions targeting European healthcare systems and GDPR-ready health data platforms.

What specific problems do the top-funded startups solve and what innovations do they bring?

AI-driven diagnostics companies like Freenome tackle early disease detection through blood-based cancer screening, achieving 95%+ sensitivity rates compared to traditional screening methods that often miss early-stage cancers.

Which technologies and R&D breakthroughs attracted the most investor attention?

Generative AI applications captured 45% of digital health funding in H1 2025, with investors specifically targeting clinical workflow automation, diagnostic imaging enhancement, and drug discovery acceleration platforms.

Large language models (LLMs) customized for healthcare documentation attracted significant investment, with companies like Abridge proving 60-70% time savings for physicians. Computer vision AI for medical imaging reached commercial viability, with startups like Koios Medical achieving FDA breakthrough designation for breast cancer detection.

TechBio platforms combining computational biology with AI drug discovery secured massive rounds, as seen in Xaira's $1 billion raise and Formation Bio's $375 million Series D. These platforms promise 40% faster clinical trial timelines and 25% cost reductions compared to traditional pharmaceutical development.

Digital therapeutics (DTx) with proven clinical outcomes gained traction, particularly for mental health and chronic disease management. Investors focused on platforms with FDA approval, published clinical evidence, and clear reimbursement pathways through Medicare Advantage and commercial payers.

Wondering who's shaping this fast-moving industry? Our slides map out the top players and challengers in seconds.

Are major tech, pharma, or insurance companies directly investing in these startups?

Pharmaceutical giants like Roche directly led Freenome's $254 million Series E round, seeking early access to AI-powered cancer screening technologies that complement their oncology drug portfolio.

Google Ventures (GV) deployed over $500 million across 160+ digital health investments, with particular focus on AI diagnostics, clinical decision support, and healthcare data platforms that integrate with Google Cloud's healthcare APIs. Microsoft's venture arm backed several electronic health record (EHR) optimization startups through their $1 billion Climate Innovation Fund.

Insurance giants like Anthem and Humana invested directly in benefits navigation platforms like Transcarent, seeking 15-20% cost reductions for their member populations. CVS Health Ventures and Walgreens Boots Alliance Ventures actively funded telehealth and digital pharmacy startups to defend against Amazon's healthcare expansion.

Amazon Web Services (AWS) launched a $100 million healthcare accelerator program, providing cloud credits and technical support to startups building on their HIPAA-compliant infrastructure. Nvidia's venture arm specifically targeted medical imaging AI companies that leverage their GPU technology for real-time diagnostic processing.

If you want to build or invest on this market, you can download our latest market pitch deck here

Which geographic regions show the strongest digital health investment activity?

The United States maintained its leadership with 57% of global digital health funding in H1 2025, though this represents a decline from 67% in 2024 as international markets gained sophistication.

Europe experienced a breakthrough quarter in Q1 2025, capturing 23% of global funding compared to 15% in 2024, driven by regulatory clarity around AI medical devices and GDPR-compliant health data platforms. The UK, Germany, and France led European activity with $2.8 billion in combined funding.

Asia-Pacific maintained steady 18-20% market share, with Singapore emerging as a Southeast Asian hub for digital health innovation. China's digital health market faced regulatory constraints but still generated $1.2 billion in funding, primarily for hospital information systems and AI diagnostics platforms.

Emerging markets showed promise, with India capturing $800 million in funding led by PharmEasy's $216 million round, while Latin America generated $400 million primarily for telemedicine and digital pharmacy platforms serving underserved populations.

What trends emerged in business models and healthcare verticals during this funding cycle?

Mental health platforms dominated vertical-specific funding, with companies like Talkiatry raising $130 million by proving direct-pay and insurance reimbursement models that achieve 40%+ gross margins.

• Subscription-based telehealth: Companies offering unlimited consultations for $99-199/month captured significant market share, particularly for chronic disease management and preventive care.
• AI-powered clinical workflows: Platforms reducing physician administrative burden by 60-70% attracted premium valuations due to measurable ROI for healthcare systems.
• Direct-pay specialty care: High-margin services like dermatology, psychiatry, and fertility treatments proved sustainable outside traditional insurance models.
• Enterprise health benefits: B2B platforms helping employers reduce healthcare costs by 15-20% secured large corporate contracts with multi-year commitments.
• Digital therapeutics with clinical evidence: FDA-approved DTx platforms for diabetes, depression, and PTSD commanded higher valuations due to proven clinical outcomes.
• Marketplace models: Platforms connecting patients with specialized providers showed strong network effects and 25-30% take rates on transactions.

What were typical funding terms and valuations for the largest rounds?

Mega-deals ($100+ million) typically involved 10-15% equity dilution for growth-stage companies, with pre-money valuations ranging from $800 million to $3 billion depending on revenue multiples and market leadership position.

Series D and later rounds commanded revenue multiples of 8-15x for companies with proven unit economics and clear paths to profitability. Xaira Therapeutics' $1 billion strategic round represented a unique structure with pharmaceutical partnerships providing both capital and regulatory expertise.

Strategic investors like Roche's investment in Freenome included exclusive licensing options and co-development agreements, reducing traditional venture capital returns but providing market validation and regulatory support. Down rounds affected 15-20% of companies, particularly those without clear revenue models or clinical validation.

Liquidation preferences remained standard 1x non-participating for most rounds, though some late-stage deals included anti-dilution provisions and board composition requirements. Founders typically retained 15-25% ownership after Series C/D rounds, depending on capital efficiency and milestone achievement.

Looking for the latest market trends? We break them down in sharp, digestible presentations you can skim or share.

If you need to-the-point data on this market, you can download our latest market pitch deck here

Which companies are positioned to raise significant funding in 2026?

Companies with 12+ months of runway and proven revenue growth exceeding $50 million ARR are prime candidates for 2026 mega-deals, particularly those demonstrating clear paths to profitability.

AI diagnostics platforms achieving FDA breakthrough designations signal readiness for growth rounds, as regulatory approval validates clinical efficacy and opens reimbursement pathways. Several stealth-mode companies in drug discovery and clinical trials automation have indicated plans for $200-500 million Series C/D rounds.

Digital therapeutics companies with published clinical trial results and Medicare coverage decisions will likely command premium valuations in 2026. Mental health platforms expanding beyond therapy into psychiatry and medication management represent significant funding opportunities.

Healthcare infrastructure companies serving enterprise clients with annual contracts exceeding $10 million demonstrate sticky revenue models attractive to growth investors. International expansion by US companies and US market entry by European platforms will drive cross-border investment activity.

How is investor sentiment evolving and what should new entrants monitor?

Investor sentiment shifted from "growth at all costs" to "selective scale," prioritizing companies with proven unit economics, regulatory approval pathways, and clear competitive moats over rapid user acquisition.

Due diligence timelines extended from 6-8 weeks to 12-16 weeks as investors demand comprehensive clinical evidence, regulatory strategy, and reimbursement validation before committing capital. Companies without 18+ months of runway face challenging fundraising environments.

AI clinical impact measurement became paramount, with investors requiring proof of 20%+ cost reduction or 30%+ efficiency improvement versus existing solutions. Strategic corporate partnerships with health systems, pharmaceutical companies, or insurance providers validate market fit and reduce investor risk.

New entrants should monitor evolving FDA AI/ML guidance, EU Medical Device Regulation updates, and changing reimbursement policies that directly impact market access and revenue potential. Geographic diversification opportunities exist as European and Asian markets develop more sophisticated healthcare technology adoption frameworks.

Planning your next move in this new space? Start with a clean visual breakdown of market size, models, and momentum.

Conclusion

Sources

1. Galen Growth - AI and TechBio Funding Lead the Charge
2. Fierce Healthcare - Digital Health Venture Funding
3. Galen Growth - Asia Pacific Digital Health Funding
4. Galen Growth - Q2 2025 Mid-Year Pulse Check
5. MedCity News - Digital Health Investment Funding
6. Galen Growth - H1 2024 Digital Health Funding
7. Fierce Healthcare - Q1 Digital Health Startups
8. Healthcare Brew - Digital Health VC Funding Evolution
9. Accretive Edge - Digital Health Investors 2025
10. Galen Growth - Big Tech in Digital Health Innovation
11. Seedtable - Digital Health Investors
12. Vestbee - Top Health Tech VC Funds in Europe
13. Eularis - Big Tech Healthcare Moves
14. CB Insights - Big Tech Healthcare Report
15. Galen Growth - Rise of Big Tech in Healthcare
16. Galen Growth - Q1 2025 Digital Health Funding
17. LinkedIn - Digital Health Market Update April 2025
18. Healthcare Dive - Digital Health Funding Declines
19. Rock Health - 2024 Year End Market Overview
20. Rock Health - Q1 2025 Market Overview